Nexvax2

BIOLOGICAL3 trials

Sponsors

ImmusanT, Inc.

Conditions

Autoimmune DiseasesCeliacCeliac DiseaseCoeliac DiseaseDigestive System DiseaseDigestive System DiseasesGastrointestinal DiseaseGluten Sensitivity

Phase 1

Safety and Tolerability of Nexvax2 in Subjects With Celiac Disease

CompletedNCT02528799

ImmusanT, Inc.Celiac Disease

Start: 2015-08-31End: 2017-01-06Updated: 2018-12-24

Bioequivalence Study of Nexvax2 in Subjects With Celiac Disease

CompletedNCT03543540

ImmusanT, Inc.Celiac Disease, Coeliac Disease, Digestive System Diseases +5

Start: 2018-05-01End: 2018-09-10Updated: 2018-09-20

Phase 2

A Study of the Safety, Efficacy and Tolerability of Nexvax-2 in Patients With Celiac Disease (CeD)

ImmusanT, Inc.Autoimmune Diseases, Celiac, Celiac Disease +5

Start: 2018-08-06End: 2019-09-30Target: 146Updated: 2019-03-19

Related Papers

Efficacy and safety of gluten peptide-based antigen-specific immunotherapy (Nexvax2) in adults with coeliac disease after bolus exposure to gluten (RESET CeD): an interim analysis of a terminated randomised, double-blind, placebo-controlled phase 2 study.

2023-03-0720 citations

Patient factors influencing acute gluten reactions and cytokine release in treated coeliac disease.

2020-11-2635 citations

Epitope-Specific Immunotherapy Targeting CD4-Positive T Cells in Celiac Disease: Safety, Pharmacokinetics, and Effects on Intestinal Histology and Plasma Cytokines with Escalating Dose Regimens of Nexvax2 in a Randomized, Double-Blind, Placebo-Controlled Phase 1 Study.

2017-11-2244 citations